Novozymes Biopharma Signs License Agreement with GE Healthcare to Produce and Sell Protein A

11-Mar-2009 - United Kingdom

Novozymes Biopharma UK Ltd., part of Novozymes, announced a newly signed license agreement with GE Healthcare Life Sciences. This license enables Novozymes Biopharma to produce and deliver native, animal-free protein A using GE Healthcare technology. Novozymes Biopharma's protein A, which is now commercially available, is targeted to customers involved in the production of chromatography media.

Protein A is produced by Novozymes Biopharma AB in Sweden using both GE Healthcare's proprietary technology and production strain. The protein is the active component in chromatography media used in the production of antibodies. Novozymes' protein A can then be used to purify antibodies in drug production and bio-chemical analysis applications.

In nature, the microorganism, Staphylococcus aureus utilises protein A to bind antibodies in order to hide itself from the immune system when invading the body. The ability of protein A to bind to antibodies has been used successfully at industrial scale for several years to produce monoclonal antibodies that are used as drugs in the treatment of illnesses such as arthritis and cancer.

Other news from the department research and development

Most read news

More news from our other portals

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic World Chromatography

Chromatography enables us to separate, identify and thus understand complex substances. Whether in the food industry, pharmaceutical research or environmental analysis - chromatography opens up a treasure trove of information about the composition and quality of our samples. Discover the fascinating world of chromatography!

50+ products
10+ whitepaper
45+ brochures
View topic world
Topic World Chromatography

Topic World Chromatography

Chromatography enables us to separate, identify and thus understand complex substances. Whether in the food industry, pharmaceutical research or environmental analysis - chromatography opens up a treasure trove of information about the composition and quality of our samples. Discover the fascinating world of chromatography!

50+ products
10+ whitepaper
45+ brochures

Last viewed contents

Biotech has Positive Year Despite Weak Fourth Quarter Performance - Burrill looks back at 2007

Nanoscale ruler reveals organization of the cell membrane - Freiburg biologists measure distances and the arrangement of membrane molecules in nanometer range

Nanoscale ruler reveals organization of the cell membrane - Freiburg biologists measure distances and the arrangement of membrane molecules in nanometer range

Australia’s Top 20 cancer drugs to reach sales of $1 billion by 2018

Tripos to Build One of the Leading Informatics-Driven Drug Discovery Laboratories in Europe - - State-of-the-Art Chemical Synthesis Facilities to be Built in Cornwall, England -

5 Leading Multinationals Announce R&D Projects for Ireland - Bristol-Myers Squibb Company, Pfizer Inc., Genzyme Corporation, Xilinx Inc. Citigroup are investing a total of EUR 53.25 million

Pesticides and other common chemical pollutants are toxic to our ‘good’ gut bacteria

Pesticides and other common chemical pollutants are toxic to our ‘good’ gut bacteria

Munich-based lab automation startup raised €2.77M - AI-driven biotech research: Connected labs for faster scientific progress

Munich-based lab automation startup raised €2.77M - AI-driven biotech research: Connected labs for faster scientific progress

How machine learning, data integration and AI contribute to better strategies in the fight against pathogens - Researchers develop a new machine learning approach

How machine learning, data integration and AI contribute to better strategies in the fight against pathogens - Researchers develop a new machine learning approach

Gene_therapy

Adapting the Power of Density Gradient Separations for Gene Therapy Analytics - DGE-AUC (Density Gradient Equilibrium AUC) highly simplified analytical method

Adapting the Power of Density Gradient Separations for Gene Therapy Analytics - DGE-AUC (Density Gradient Equilibrium AUC) highly simplified analytical method

Fast and Reproducible AAV Quantification - Fast, Direct, and Label-free Quantitation of AAV Capsids in Bioprocess Control

Fast and Reproducible AAV Quantification - Fast, Direct, and Label-free Quantitation of AAV Capsids in Bioprocess Control

Purifying mRNA using the original PS-DVB columns and buffers for new vaccines development - Messenger RNA Purification and Production with highest purity for the development of novel vaccines

Purifying mRNA using the original PS-DVB columns and buffers for new vaccines development - Messenger RNA Purification and Production with highest purity for the development of novel vaccines